NY-ESO-1 TCR Engineered T Cells and HSCs (Roswell Park Cancer Institute) | Interleukin Related interleukin-related.com

Product Name :
NY-ESO-1 TCR Engineered T Cells and HSCs (Roswell Park Cancer Institute)

Search keywords :
HLA-DP

drugId :
null

Target Vo:
Cancer/testis antigen 1

Target Vo Short Name :
NY-ESO-1

Moa_Name:
Anti-NY-ESO-1

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Roswell Park Cancer Institute

Active Company_Name :
Roswell Park Cancer Institute

Active Indication_Name:
Peritoneal Neoplasms

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 1 Clinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Osocimab Cancer
PDK1 Rabbit mAb medchemexpress
Phospho-AKT1(Ser473) Antibody: Phospho-Akt1(Ser473) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 56 kDa, targeting to Phospho-Akt1(Ser473). It can be used for WB,ICC/IF,IHC-P assays with tag free, in the background of Human, Mouse.

Author: Interleukin Related

Related Posts